This prospective study explored an optimal conditioning regimen to ensure engraftment with minimal toxicity in adult patients with severe aplastic anemia (SAA) who received haplo-identical stem cell transplantation from a related mismatched donor (Haplo-SCT). We explored a safe and sufficient dose of rabbit ATG (Thymoglobulin) in combination with 800 cGy total body irradiation (TBI) and fludarabine (Flu, 30 mg/m 2 /day) for 5 days using step-by-step dose de-escalation.
| INTRODUCTION
Although allogeneic stem cell transplantation (SCT) from an HLAmatched sibling donor (MSD-SCT) is the most preferred first-line treatment option for younger severe aplastic anemia (SAA) patients, 1, 2 only 25% of patients have the chance of finding an HLA-matched sibling donor. 3 In SAA patients who lack a suitable MSD and fail first-line immune suppressive therapy (IST), SCT from an unrelated donor (URD-SCT) offers a treatment option. But it requires considerable time and costs, which could be inacceptable, especially for very SAA (VSAA) patients in urgent need of transplantation. 2, 4 Haplo-identical stem cell transplantation from a related mismatched donor (Haplo-SCT) is recognized as having better results due to recent advances in controlling graft failure (GF) and graft-vs-host disease (GVHD). Therefore, the usage of Haplo-SCT has extended into SAA. Several studies using different conditioning regimens including a small number of SAA patients who received Haplo-SCT have reported variable outcomes, with survival rates reaching 67%-100% after a relatively short follow-up and GF rates ranging from about 3.8%-25%. [5] [6] [7] [8] [9] Recent studies of Haplo-SCT in SAA have included a multicenter study in a large number of patients with upfront SCT strategy. [10] [11] [12] However, an optimal conditioning regimen and strategy of graft manipulations in adult patients with acquired SAA have not been systemically evaluated in Haplo-SCT.
In this study, we explored a feasible conditioning regimen to ensure engraftment with minimal toxicity in adult patients with SAA who received Haplo-SCT. and was conducted in accordance with the Declaration of Helsinki.
| MATERIALS AND METHODS

| Study patients
| Study design and transplant procedures
Supporting Information Figure 1 shows the study scheme. We All donors and patients were typed for HLA-A, HLA-B, HLA-C, and DRB1 loci by high-resolution DNA techniques. For each pair, the patient shared one haplotype and showed some degree of mismatch with the other (Table 1) . For GVHD prophylaxis, a combination of tacrolimus (Astellas Pharma Korea, Inc.) and short-course methotrexate (MTX) (5 mg/m 2 i.v. bolus injection on days +1, +3, +6, and +11) was used. Tacrolimus was administered by continuous infusion intravenously (i.v.) with a starting dose of 0.03 mg/kg from day −1 to +21, and then orally at a total of 0.12 mg/kg/day. Individualized dosage adjustment of tacrolimus was based on plasma level to maintain a target dose of 5-15 ng/mL. Tacrolimus was tapered from day +90 after transplant in the absence of acute GVHD. G-CSF-mobilized peripheral blood stem cells (PBSCs) were used as a stem cell source without manipulation. Donor-specific HLA antibody (DSA) test was performed since July 2013 and positive DSA was allowed for enrollment in this study.
| Supportive care and monitoring for CMV infection
G-CSF (lenograstim) (5 μg/kg per day) was administered subcutaneously to all patients from day +7 after transplantation until the absolute neutrophil count (ANC) was >3.0 × 10 9 /L. Lipo-prostaglandin E1
(1 μg/kg/day) was administered with ursodiol (200 mg thrice daily) for the prevention of sinusoidal obstruction syndrome (SOS). 
| Definitions
Neutrophil and platelet engraftment were defined as an ANC >0.5 × 10 9 /L on the first three consecutive days and a platelet count >20 × 10 9 /L without transfusion support on the first seven consecutive days, respectively. Failure to engraft by day 28 was considered primary GF. Secondary GF was defined as an initial engraftment with documented donor-derived hematopoiesis, followed by loss of graft function. Acute and chronic GVHD were graded according to the clinical consensus criteria. 16, 17 AA severity was defined according to previously published criteria. 18 Causes of death were categorized according to the scheme proposed by Copelan et al. 19 
| Statistical analyses
The primary objective of this study was to explore an optimal conditioning dose of ATG and TBI to ensure engraftment with minimal toxicity in adult patients with SAA who received Haplo-SCT. The major endpoints were GF, GVHD, TRM, GVHD-and failure-free survival (GFFS), and overall survival (OS) rates. GFFS was measured from transplantation to grade 3-4 GVHD, chronic GVHD requiring systemic treatment, primary or secondary GF, or death, whichever came first. 20 The events for TRM and OS were defined as deaths without GF and death of any cause, respectively. The probabilities of GFFS and OS were calculated using Kaplan-Meier estimates and compared using the log-rank test. Curves for TRM and GVHD were plotted according to cumulative incidence estimates and compared with the Gray test.
All statistical analyses were performed using the Statistical Package for Social Sciences, version 14.0 (SPSS Inc., Chicago, IL). Cumulative incidence analyses were carried out with R software version 2.15.1
(R Foundation for Statistical Computing, 2012). Statistical significance was set at a P value <0.05.
3 | RESULTS
| Patients and transplantation characteristics
The median age (20 
| Engraftment
All patients achieved neutrophil engraftment at a median of 12 days after transplant (range 11-12). During the follow-up period, 32 (94.1%) patients achieved platelet engraftment after a median of Abbreviations: CMV, cytomegalovirus; D, donor; Flu, fludarabine; HSCT, hematopoietic stem cell transplantation; IST, immunosuppressive treatment; Mod, moderate; ND, not done; PLT, platelet; PNH, paroxysmal nocturnal hemoglobinuria; R, recipient; RBC, red blood cell; rATG, rabbit antithymocyte globulin; TBI, total body irradiation. a trisomy 8 (n = 1) and inversion 9 (n = 1) at baseline disappeared after HSCT. b PNH cells (n = 3) disappeared 2-3 months after HSCT. c Strong (MFI > 10 000), Moderate (MFI 5000-10 000), Weak-Moderate (MFI 3000-5000), Weak (MFI 1000-3000) using Luminex single antigen bead assay.
14 days (range 5 Table 2 .
| Early complications and GVHD
Thirteen patients ( CMV DNAemia requiring pre-emptive therapy, n (%) Abbreviations: ANC, absolute neutrophil count; CMV, cytomegalovirus; GVHD, graft-vs-host disease; PLT, platelet; PTLD, posttransplant lymphoproliferative disorder. a Two patients with secondary GF exhibited donor chimerism of 45% and 13%, respectively.
| Survival and GVHD-free survival
With a median follow-up of 26.3 (9.1-64.0) months (56.6 and 21.8 months in groups 1-3 and group 4, respectively), the 2-year probability of overall survival was 84.6 AE 6.4%. The 2-year probability of OS in groups 1-3 and group 4 was 70.0 AE 14.5% and 91.7 AE 5.6%
(P = 0.155), respectively (Figure 2A,B) .
Given the importance of both survival and GVHD rate for testing conditioning regimens, the 2-year probability of GFFS was also addressed. The 2-year probability of GFFS was 70.2 AE 7.9%, indicating that GVHD-free survival tended to be better in group 4 compared to groups 1-3 (78.4% in group 4 vs 50% in groups 1-3, P = 0.115), although the difference did not reach statistical significance ( Figure 2C,D) .
| Immune reconstitution
Lymphocyte subset data were analyzed, and those data were available 
| DISCUSSION
Transplantation using a related mismatched donor is challenging.
5,21,22
A graft from a related mismatched donor is available for most patients and has the advantages of prompt accessibility and low cost. However, until now, data have been insufficient to make a recommendation regarding graft composition and conditioning regimen for Haplo-SCT in SAA. 23 In this study, we explored optimal conditioning with step-by-step dose de-escalation of ATG and TBI to reduce TRM with sustained graft function. TBI-600 cGy/Flu/intermediate-dose ATG resulted in feasible outcomes of Haplo-SCT for adult patients with SAA, indicated by the 91.7% OS and 78.4% GFFS rates. These outcomes were comparable to those of URD-SCT reported in our previous study. 24 In URD-SCT for adult patients with SAA, OS, and GFFS
rates were approximately 84.0%-92.3% and 30.8%-62.5% according to the use of ATG, respectively. However, these results should be interpreted with caution due to the possibility of differences in patient tioning regimen, such as one containing TBI, to achieve sustained engraftment. 25 Tzeng et al. also added TBI 800 cGy to cyclophosphamide (Cy) 200 mg/kg to achieve sustained engraftment. 26 Xu et al. evaluated a conditioning regimen including busulfan, Cy, and ATG in SAA patients who received a combination of G-CSF-primed BM and G-CSF-mobilized PBSCs from haploidentical family donors.
All patients achieved 100% donor myeloid engraftment. The OS was 64% with a median 746 days of follow-up for surviving patients.
However, the reported incidence of chronic GVHD was 56%. 21 In addition to these previous studies with a small number of AA patients receiving Haplo-SCT, recent studies of Haplo-SCT in SAA included a multicenter study in a large number of patients with upfront SCT strategy, [10] [11] [12] as summarized in the Supporting Information Table I .
However, because previous studies (Supporting Information Table I) enrolled both pediatric and adult patients, our results from a homogeneous population of adult patients with acquired SAA are better suited to help establish optimal conditioning procedures.
The main concern in determining an optimal conditioning regimen in adult patients with SAA who received Haplo-SCT is successful engraftment with minimal toxicity. Successful engraftment is particularly desirable because GF is more common in patients with SAA compared to patients with acute leukemia, [27] [28] [29] and early-onset GF is associated with a high risk of infection and mortality. Accordingly, we first explored a safe and sufficient dose of ATG in combination with 800 cGy TBI and Flu using step-by-step dose de-escalation, where the dose of ATG was de-escalated from 10 mg/kg, to 7.5 mg/kg, to 5 mg/kg based on the occurrence of TRM. Next, the TBI dose was also reduced to 600 cGy with a fixed dose of Flu and ATG (5 mg/kg).
In this study, the initial fractionated 800 cGy TBI- FIGURE 2 Two-year probability of overall survival in total patients (A) and comparison between groups 1-3 and group 4 (B). Two-year probability of GVHD-and failure-free survival in total patients (C) and comparison between groups 1-3 and group 4 (D)
In terms of GVHD prophylaxis, we used a combination of tacrolimus and short-course MTX. We started tapering of tacrolimus from day +90 and slowly reduced dose over 1 year in the absence of GVHD. A matched-pair analysis conducted by the Japan Marrow Donor Program (JMDP) comparing the outcomes between tacrolimus and cyclosporin with MTX as GVHD prophylaxis in URD-SCT setting demonstrated that the tacrolimus/MTX group showed a higher OS (P = 0.012) with a lower trend for incidence of chronic GVHD (P = 0.104). 32 Although many SCT centers used posttransplant cyclophosphamide (PTCY) protocol in Haplo-SCT, 33 proper strategies for GVHD prophylaxis remain to be defined in patients with SAA.
There have been a few reports of Haplo-SCT with TBI-based conditioning for AA. 8, 9 Im et al. reported that 3 of 12 patients receiving
Haplo-SCT with T cell-depleted grafts experienced GF, including early graft rejection in 2 patients. In their study, GF occurred in 3 of 6 patients who did not receive TBI, but did not occur in 6 patients who received 400 cGy TBI. Although these numbers are too small to justify TBI-based conditioning for Haplo-SCT in SAA, we can also learn from experiences in conditioning regimens of URD-SCT for patients with SAA. We previously reported early results from a pilot prospective study to determine the dose of TBI to be used in combination with 120 mg/kg of Cy as a conditioning regimen for URD-SCT in adult patients with SAA, which demonstrated the superiority of 800 cGy of TBI compared to higher doses of TBI (1000 and 1200 cGy). 34 Later, we extended our experience, showing the feasibility of 800 cGy of TBI in combination with 120 mg/kg of Cy with engraftment of all patients. 14,24 A TBI dose de-escalation strategy for reducing transplant-related toxicity without jeopardizing engraftment has also been reported. 35, 36 In terms of the dose of ATG, five patients received ATG (10 mg/kg), while the fifth of this group died due to severe lung GVHD and CMV pneumonia. Thereafter, we reduced the dosage of ATG to 7.5 mg/kg. In addition, two patients and 1 patient receiving ATG 10 mg/kg (group 1) and 7.5 mg/kg (group 2), respectively, developed EBV-associated PTLD. According to the same strategy, we reduced the dose of ATG to 5 mg/kg (group 3). Patients with SAA do not require a graft-vs-tumor effect after allogeneic SCT, and GVHD is a detrimental factor affecting long-term outcomes after allogeneic SCT in SAA in terms of mortality and morbidity associated with poor quality of life. 37 In the current study, the patients receiving TBI-600 cGy/Flu/intermediate-dose ATG (group 4) showed no significant differences in the incidence of acute and chronic GVHD compared with patients in groups 1-3, suggesting that intermediate-dose ATG could play a protective role against acute and chronic GVHD. Considering the importance of both survival and GVHD rate, we also analyzed GFFS and found that the rate in group 4 tended to be higher than that in groups 1-3, although the difference did not reach statistical significance. As the follow-up duration of group 4 was relatively short and this may impact the incidence of chronic GVHD, further follow-up is needed. In previous reports, ATG was found to reduce the incidence of GVHD, but excessive doses of ATG (>7.5 mg/kg) resulted in higher incidences of GF, toxicity, severe infection, and PTLD. [38] [39] [40] [41] However, an optimal dose of ATG for Haplo-SCT in SAA has yet to be established. Three studies using total doses of 10-12.5 mg/kg of ATG reported acute GVHD (grade ≥ 2) rates of 30.3%-38.5% and chronic GVHD rates of 25.8%-39.3%. [10] [11] [12] For the further development of Haplo-SCT as a treatment for adult patients with SAA, data from a uniform protocol including a large number of patients are needed.
In conclusion, this study explored an optimal conditioning regimen with step-by-step de-escalation dose of ATG and TBI to reduce TRM with sustained graft function. TBI-600 cGy/Flu/intermediate-dose
ATG resulted in feasible outcomes of Haplo-SCT for adult patients with SAA.
